Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans

mBio

Volumn 2, Issue 5, 2011, Pages

  Agarwal, Sarika ^a   Specht, Charles A ^a   Huang, Haibin ^a   Ostroff, Gary R ^b   Ram, Sanjay ^a   Rice, Peter A ^a   Levitz, Stuart M ^a  

^a Department of Medicinea and Program in Molecular Medicine ^*  (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHITIN; CHITOSAN; GLYCAN; GLYCOSIDE; MANNAN; MONOSACCHARIDE; PROPERDIN; ZYMOSAN;

ARTICLE; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CELL WALL; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SPECIFICITY; FUNGAL CELL; FUNGUS; LINKAGE ANALYSIS; LIPID STORAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

FUNGI;

EID: 80455127043     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00178-11     Document Type: Article

References (53)

1. Casadevall A, Feldmesser M, Pirofski LA. 2002. Induced humoral immunity and vaccination against major human fungal pathogens. Curr. Opin. Microbiol. 5:386-391.
2. Han Y, et al. 2001. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J. Immunol. 167:1550-1557.
3. Kozel TR. 1996. Activation of the complement system by pathogenic fungi. Clin. Microbiol. Rev. 9:34-46.
4. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. 1981. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition ofC3b-like activitiesby spontaneous hydrolysisofthe putative thio-ester in native C3. J. Exp. Med. 154:856-867.
5. Sim RB, Twose TM, Paterson DS, Sim E. 1981. The covalent-binding reaction of complement component C3. Biochem. J. 193:115-127.
6. Fearon DT, Austen KF. 1975. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 142:856-863.
7. Fijen CA, et al. 1999. Properdin deficiency: molecular basis and disease association. Mol. Immunol. 36:863-867.
8. Nolan KF, Reid KB. 1993. Properdin. Methods Enzymol. 223:35-46.
9. Pangburn MK. 1989. Analysis of the natural polymeric forms of human properdin and their functions in complement activation. J. Immunol. 142:202-207.
10. Schwaeble WJ, Reid KB. 1999. Does properdin crosslink the cellular and the humoral immune response? Immunol. Today 20:17-21.
11. Xu W, et al. 2008. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J. Immunol. 180:7613-7621.
12. Wirthmueller U, et al. 1997. Properdin, a positive regulator of complement activation,isreleased from secondary granules ofstimulated peripheral blood neutrophils. J. Immunol. 158:4444-4451.
13. Figueroa J, Andreoni J, Densen P. 1993. Complement deficiency states and meningococcal disease. Immunol. Res. 12:295-311.
14. Figueroa JE, Densen P. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4:359-395.
15. Ross SC, Densen P. 1984. Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63:243-273.
16. Klis FM, de Groot P, Hellingwerf K. 2001. Molecular organization of the cell wall of Candida albicans. Med. Mycol. 39(Suppl. 1):1-8.
17. Klis FM, Mol P, Hellingwerf K, Brul S. 2002. Dynamics of cell wall structure in Saccharomyces cerevisiae. FEMS Microbiol. Rev. 26:239-256.
18. Magnelli P, Cipollo JF, Abeijon C. 2002. A refined method for the determination of Saccharomyces cerevisiae cell wall composition and beta-1,6-glucan fine structure. Anal. Biochem. 301:136-150.
19. Kapteyn JC, Van Den Ende H, Klis FM. 1999. The contribution of cell wall proteins to the organization of the yeast cell wall. Biochim. Biophys. Acta 1426:373-383.
20. Aouadi M, et al. 2009. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458:1180-1184.
21. Soto ER, Ostroff GR. 2008. Characterization of multilayered nanopar-ticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug. Chem. 19:840-848.
22. Novak M, Vetvicka V. 2008. Beta-glucans, history, and the present: im-munomodulatory aspects and mechanisms of action. J. Immunotoxicol. 5:47-57.
23. Weitberg AB. 2008. A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy. J. Exp. Clin. Cancer Res. 27:40.
24. Williams DL, et al. 1988. Pre-clinical safety evaluation of soluble glucan. Int. J. Immunopharmacol. 10:405-414.
25. Czop JK, Austen KF. 1985. Properties of glycans that activate the human alternative complement pathway and interact with the human monocyte beta-glucan receptor. J. Immunol. 135:3388-3393.
26. Pillemer L, et al. 1954. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120:279-285.
27. Agarwal S, et al. 2010. An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonor-rhoeae. J. Immunol. 185:507-516.
28. Hourcade DE. 2006. The role of properdin in the assembly of the alternative pathway C3 convertases of complement. J. Biol. Chem. 281: 2128-2132.
29. Ferreira VP, Cortes C, Pangburn MK. 2010. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. Immunobiology 215:932-940.
30. Mitchell LM, Hourcade D. 2008. Inhibition of properdin-directed complement activation by serum amyloid P component. Mol. Immunol. 45: 4103.
31. Hong F, et al. 2004. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J. Immunol. 173:797-806.
32. Holan Z, Beran K, Miler I. 1980. Preparation of zymosan from yeast cell walls. Folia Microbiol. (Praha) 25:501-504.
33. Young SH, et al. 2007. A comparison of the pulmonary inflammatory potential of different components of yeast cell wall. J. Toxicol. Environ. Health A 70:1116-1124.
34. Hadas S, Reichert F, Rotshenker S. 2010. Dissimilar and similar functional properties of complement receptor-3 in microglia and macro-phages in combating yeast pathogens by phagocytosis. Glia 58:823-830.
35. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. 2010. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. mBio 1:e00164-10.
36. Huang H, et al. 2009. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and Toll-like receptor agonists. Infect. Immun. 77:1774-1781.
37. Chuah CT, Sarko A, Deslandes Y, Marchessault RH. 1983. Triple-helical crystalline structure of curdlan and paramylon hydrates. Macromolecules 16:1375-1382.
38. Sahu A, Kozel TR, Pangburn MK. 1994. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation. Biochem. J. 302(Part 2):429-436.
39. Camous L, et al. 2011. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 117:1340-1349.
40. Rubin-Bejerano I, Abeijon C, Magnelli P, Grisafi P, Fink GR. 2007. Phagocytosis by human neutrophils is stimulated by a unique fungal cell wall component. Cell Host Microbe 2:55-67.
41. Lajoie S, et al. 2010. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat. Immunol. 11:928-935.
42. Ricklin D, Hajishengallis G, Yang K, Lambris JD. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
43. Stuehler C, et al. 2011. Cross-protective TH1 immunity against Aspergil-lus fumigatus and Candida albicans. Blood 117:5881-5891.
44. Wüthrich M, et al. 2011. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J. Clin. Invest. 121:554-568.
45. Li B, et al. 2010. Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer. Clin. Cancer Res. 16:5153-5164.
46. Goodridge HS, et al. 2011. Activation of the innate immune receptor Dectin-1 upon formation of a "phagocytic synapse.". Nature 472: 471-475.
47. Gonzalez SF, et al. 2011. Trafficking of B cell antigen in lymph nodes. Annu. Rev. Immunol. 29:215-233.
48. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. 1996. C3dof complement asamolecular adjuvant: bridging innate and acquired immunity. Science 271:348-350.
49. Di Carlo FJ, Fiore JV. 1958. On the composition of zymosan. Science 127:756-757.
50. O'Rear LD, Ross GD. 2001. Isolation and purification of C3 from human plasma. Curr. Protoc. Immunol. Chapter 13, Unit 13.3.
51. Madico G, et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510.
52. Ram S, et al. 2001. Binding of C4b-binding protein to porin: a molecular mechanism of serum resistance of Neisseria gonorrhoeae. J. Exp. Med. 193:281-295.
53. Lewis LA, et al. 2008. Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect. Immun. 76:339-350.